NetworkNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre- and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point. ‘These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction,’ said Eric Weisblum, CEO of Silo Pharma. ‘This data is extremely promising for patients suffering from fibromyalgia and rheumatoid arthritis…,’” a recent article reads. “Silo Pharma aims to leverage the effects of ketamine via a patented administration method developed in partnership with Zylo Therapeutics Inc. called ‘Z-pod.’ The company’s ketamine study aimed to demonstrate that Z-pod can hold and distribute ketamine and time-release the drug while diminishing potential hallucinogenic side effects.” To view the full article, visit https://nnw.fm/wgRdd About Silo Pharma Inc. Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://nnw.fm/SILO About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit https://www.networknewswire.com Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer NetworkNewsWire (NNW) New York, New York www.networknewswire.com 212.418.1217 Office Editor@NetworkNewsWire.com NetworkNewsWire is part of the InvestorBrandNetwork